Feasibility, Efficacy, and Mechanisms of Surgical vs Medical Diabetes Treatment View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2015

ABSTRACT

The escalating pandemics of obesity and type 2 diabetes mellitus (T2DM) are among the most significant contributors to morbidity and mortality worldwide. Roux-en-Y gastric bypass (RYGB) surgery causes profound weight loss and dramatically ameliorates T2DM through mechanisms beyond just weight loss, but its role in diabetes management and the nature of its weight-independent anti-diabetes effects are not well established because of a paucity of appropriate randomized trials, the execution of which is hindered by numerous obstacles. The investigators therefore propose a feasibility study to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2. Detailed Description The overall goal of the research study is to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2. Our cohort recruitment strategy will utilize the GH administrative and clinical databases to identify patients with T2DM and a BMI of 30-40 kg/m2. Sufficient numbers (N=4,000) of these individuals will be mailed and surveyed to identify the small minority without strong preferences regarding medical vs. surgical diabetes/obesity treatment. This subset will be invited to become better informed about both strategies using a novel, standardized patient decision aid for shared decision making (SDM) related to bariatric surgery: a high-quality educational video that provides balanced and frequently updated information about the risks and benefits of surgical and non-surgical care. After viewing SDM tool, potential subjects' "willingness to randomize" will be assessed, and a subset of willing patients will actually undergo randomization to either RYGB or a state-of-the-art intensive but reproducible medical/lifestyle intervention. Forty patients will be randomized to either RYGB or an intensive medical/lifestyle intervention. Twenty members will be randomly assigned to intensive behavioral/medical treatment, and twenty will be randomly assigned to receive gastric bypass surgery. In the non-surgical group, the investigators will study the feasibility and resources needed to deploy a state-of-the-art intensive behavioral intervention to promote weight loss, which includes dietary and exercise components. It will be coupled with diabetes pharmacotherapy treatment consistent with Group Health Clinical Practice Guidelines (http://incontext.ghc.org/clinical/clin_topics/diabetes2/dm2_poc.html). Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons. The operation and post-operative care will be performed at GH by Dr. Steven Bock, Dr. Jeffery Lander, and their clinical staff, including a team of nutritionists and a Registered Nurse Case Manager who coordinates the care of patients in the GH Bariatric Surgery Program. Surgical patients will also undergo a standardized 8-week pre-operative and 10-month post-operative behavioral treatment regimen with the GH Bariatric Surgery Program. Participants will have follow-up research visits at 3, 6, 9, and 12 months after randomization, where they will have the following measurements: standardized physically exam by Dr. Foster-Schubert; weight, waist and hip circumferences; systolic and diastolic blood pressure; resting 1-minute pulse; and fasting (12-hour) blood (50 ml) collection. More... »

URL

https://clinicaltrials.gov/show/NCT01295229

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The escalating pandemics of obesity and type 2 diabetes mellitus (T2DM) are among the most significant contributors to morbidity and mortality worldwide. Roux-en-Y gastric bypass (RYGB) surgery causes profound weight loss and dramatically ameliorates T2DM through mechanisms beyond just weight loss, but its role in diabetes management and the nature of its weight-independent anti-diabetes effects are not well established because of a paucity of appropriate randomized trials, the execution of which is hindered by numerous obstacles. The investigators therefore propose a feasibility study to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2.\n\nDetailed Description\nThe overall goal of the research study is to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2. Our cohort recruitment strategy will utilize the GH administrative and clinical databases to identify patients with T2DM and a BMI of 30-40 kg/m2. Sufficient numbers (N=4,000) of these individuals will be mailed and surveyed to identify the small minority without strong preferences regarding medical vs. surgical diabetes/obesity treatment. This subset will be invited to become better informed about both strategies using a novel, standardized patient decision aid for shared decision making (SDM) related to bariatric surgery: a high-quality educational video that provides balanced and frequently updated information about the risks and benefits of surgical and non-surgical care. After viewing SDM tool, potential subjects' \"willingness to randomize\" will be assessed, and a subset of willing patients will actually undergo randomization to either RYGB or a state-of-the-art intensive but reproducible medical/lifestyle intervention. Forty patients will be randomized to either RYGB or an intensive medical/lifestyle intervention. Twenty members will be randomly assigned to intensive behavioral/medical treatment, and twenty will be randomly assigned to receive gastric bypass surgery. In the non-surgical group, the investigators will study the feasibility and resources needed to deploy a state-of-the-art intensive behavioral intervention to promote weight loss, which includes dietary and exercise components. It will be coupled with diabetes pharmacotherapy treatment consistent with Group Health Clinical Practice Guidelines (http://incontext.ghc.org/clinical/clin_topics/diabetes2/dm2_poc.html). Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons. The operation and post-operative care will be performed at GH by Dr. Steven Bock, Dr. Jeffery Lander, and their clinical staff, including a team of nutritionists and a Registered Nurse Case Manager who coordinates the care of patients in the GH Bariatric Surgery Program. Surgical patients will also undergo a standardized 8-week pre-operative and 10-month post-operative behavioral treatment regimen with the GH Bariatric Surgery Program. Participants will have follow-up research visits at 3, 6, 9, and 12 months after randomization, where they will have the following measurements: standardized physically exam by Dr. Foster-Schubert; weight, waist and hip circumferences; systolic and diastolic blood pressure; resting 1-minute pulse; and fasting (12-hour) blood (50 ml) collection.", 
    "endDate": "2015-06-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01295229", 
    "keywords": [
      "feasibility", 
      "efficacy", 
      "diabetes treatment", 
      "escalating", 
      "obesity", 
      "Type 2 Diabetes Mellitus", 
      "T2DM", 
      "significant contributor", 
      "morbidity", 
      "mortality worldwide", 
      "Roux-en-Y", 
      "RYGB", 
      "General Surgery", 
      "weight loss", 
      "ameliorates", 
      "diabetes management", 
      "nature", 
      "diabetes", 
      "paucity", 
      "randomized trial", 
      "execution", 
      "obstacle", 
      "feasibility study", 
      "capacity", 
      "randomize", 
      "Group Health", 
      "overall goal", 
      "research study", 
      "recruitment strategy", 
      "GH", 
      "clinical database", 
      "patient", 
      "sufficient number", 
      "individual", 
      "small minority", 
      "strong preference", 
      "subset", 
      "standardized patient", 
      "shared decision", 
      "SDM", 
      "bariatric surgery", 
      "educational video", 
      "updated information", 
      "risk", 
      "benefit", 
      "surgical care", 
      "viewing", 
      "potential subject", 
      "Random Allocation", 
      "state-of-the-art", 
      "intervention", 
      "Health Resource", 
      "deploy", 
      "component", 
      "Clinical Practice Guidelines", 
      "arm", 
      "surgeon", 
      "operation", 
      "post-operative care", 
      "clinical staff", 
      "team", 
      "Nutritionist", 
      "nurse case manager", 
      "care", 
      "surgical patient", 
      "behavioral treatment", 
      "follow-up research", 
      "measurement", 
      "exam", 
      "weight", 
      "waist", 
      "hip circumference", 
      "systolic and diastolic blood pressure", 
      "pulse", 
      "fasting", 
      "blood", 
      "collection"
    ], 
    "name": "Feasibility, Efficacy, and Mechanisms of Surgical vs Medical Diabetes Treatment", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01295229"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00010.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.270240.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.280243.f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419635.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.280062.e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.34477.33", 
        "type": "Organization"
      }
    ], 
    "startDate": "2011-05-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s00125-016-3903-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021489722", 
          "https://doi.org/10.1007/s00125-016-3903-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00125-016-3903-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021489722", 
          "https://doi.org/10.1007/s00125-016-3903-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/oby.21927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090776719"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/oby.21927", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090776719"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01295229"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01295229'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01295229'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01295229'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01295229'


 

This table displays all metadata directly associated to this object as RDF triples.

114 TRIPLES      16 PREDICATES      99 URIs      86 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01295229 schema:about anzsrc-for:3053
2 anzsrc-for:3177
3 schema:description The escalating pandemics of obesity and type 2 diabetes mellitus (T2DM) are among the most significant contributors to morbidity and mortality worldwide. Roux-en-Y gastric bypass (RYGB) surgery causes profound weight loss and dramatically ameliorates T2DM through mechanisms beyond just weight loss, but its role in diabetes management and the nature of its weight-independent anti-diabetes effects are not well established because of a paucity of appropriate randomized trials, the execution of which is hindered by numerous obstacles. The investigators therefore propose a feasibility study to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2. Detailed Description The overall goal of the research study is to demonstrate our capacity to identify, recruit, randomize, and track outcomes for 40 adult Group Health members identified as having T2DM and a BMI between 30-40 kg/m2. Our cohort recruitment strategy will utilize the GH administrative and clinical databases to identify patients with T2DM and a BMI of 30-40 kg/m2. Sufficient numbers (N=4,000) of these individuals will be mailed and surveyed to identify the small minority without strong preferences regarding medical vs. surgical diabetes/obesity treatment. This subset will be invited to become better informed about both strategies using a novel, standardized patient decision aid for shared decision making (SDM) related to bariatric surgery: a high-quality educational video that provides balanced and frequently updated information about the risks and benefits of surgical and non-surgical care. After viewing SDM tool, potential subjects' "willingness to randomize" will be assessed, and a subset of willing patients will actually undergo randomization to either RYGB or a state-of-the-art intensive but reproducible medical/lifestyle intervention. Forty patients will be randomized to either RYGB or an intensive medical/lifestyle intervention. Twenty members will be randomly assigned to intensive behavioral/medical treatment, and twenty will be randomly assigned to receive gastric bypass surgery. In the non-surgical group, the investigators will study the feasibility and resources needed to deploy a state-of-the-art intensive behavioral intervention to promote weight loss, which includes dietary and exercise components. It will be coupled with diabetes pharmacotherapy treatment consistent with Group Health Clinical Practice Guidelines (http://incontext.ghc.org/clinical/clin_topics/diabetes2/dm2_poc.html). Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons. The operation and post-operative care will be performed at GH by Dr. Steven Bock, Dr. Jeffery Lander, and their clinical staff, including a team of nutritionists and a Registered Nurse Case Manager who coordinates the care of patients in the GH Bariatric Surgery Program. Surgical patients will also undergo a standardized 8-week pre-operative and 10-month post-operative behavioral treatment regimen with the GH Bariatric Surgery Program. Participants will have follow-up research visits at 3, 6, 9, and 12 months after randomization, where they will have the following measurements: standardized physically exam by Dr. Foster-Schubert; weight, waist and hip circumferences; systolic and diastolic blood pressure; resting 1-minute pulse; and fasting (12-hour) blood (50 ml) collection.
4 schema:endDate 2015-06-01T00:00:00Z
5 schema:keywords Clinical Practice Guidelines
6 GH
7 General Surgery
8 Group Health
9 Health Resource
10 Nutritionist
11 RYGB
12 Random Allocation
13 Roux-en-Y
14 SDM
15 T2DM
16 Type 2 Diabetes Mellitus
17 ameliorates
18 arm
19 bariatric surgery
20 behavioral treatment
21 benefit
22 blood
23 capacity
24 care
25 clinical database
26 clinical staff
27 collection
28 component
29 deploy
30 diabetes
31 diabetes management
32 diabetes treatment
33 educational video
34 efficacy
35 escalating
36 exam
37 execution
38 fasting
39 feasibility
40 feasibility study
41 follow-up research
42 hip circumference
43 individual
44 intervention
45 measurement
46 morbidity
47 mortality worldwide
48 nature
49 nurse case manager
50 obesity
51 obstacle
52 operation
53 overall goal
54 patient
55 paucity
56 post-operative care
57 potential subject
58 pulse
59 randomize
60 randomized trial
61 recruitment strategy
62 research study
63 risk
64 shared decision
65 significant contributor
66 small minority
67 standardized patient
68 state-of-the-art
69 strong preference
70 subset
71 sufficient number
72 surgeon
73 surgical care
74 surgical patient
75 systolic and diastolic blood pressure
76 team
77 updated information
78 viewing
79 waist
80 weight
81 weight loss
82 schema:name Feasibility, Efficacy, and Mechanisms of Surgical vs Medical Diabetes Treatment
83 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01295229
84 schema:sdDatePublished 2019-03-07T15:24
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N1a034e28ef5942b18bd2d4a32cd4744a
87 schema:sponsor https://www.grid.ac/institutes/grid.270240.3
88 https://www.grid.ac/institutes/grid.280062.e
89 https://www.grid.ac/institutes/grid.280243.f
90 https://www.grid.ac/institutes/grid.34477.33
91 https://www.grid.ac/institutes/grid.419635.c
92 schema:startDate 2011-05-01T00:00:00Z
93 schema:subjectOf sg:pub.10.1007/s00125-016-3903-x
94 https://doi.org/10.1002/oby.21927
95 schema:url https://clinicaltrials.gov/show/NCT01295229
96 sgo:license sg:explorer/license/
97 sgo:sdDataset clinical_trials
98 rdf:type schema:MedicalStudy
99 N1a034e28ef5942b18bd2d4a32cd4744a schema:name Springer Nature - SN SciGraph project
100 rdf:type schema:Organization
101 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
102 rdf:type schema:DefinedTerm
103 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
104 rdf:type schema:DefinedTerm
105 sg:pub.10.1007/s00125-016-3903-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1021489722
106 https://doi.org/10.1007/s00125-016-3903-x
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1002/oby.21927 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090776719
109 rdf:type schema:CreativeWork
110 https://www.grid.ac/institutes/grid.270240.3 schema:Organization
111 https://www.grid.ac/institutes/grid.280062.e schema:Organization
112 https://www.grid.ac/institutes/grid.280243.f schema:Organization
113 https://www.grid.ac/institutes/grid.34477.33 schema:Organization
114 https://www.grid.ac/institutes/grid.419635.c schema:Organization
 




Preview window. Press ESC to close (or click here)


...